IDEAYA Biosciences Inc
NASDAQ:IDYA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
25.54
47.13
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
IDEAYA Biosciences Inc
IDEAYA Biosciences Inc
Pre-Tax Income
IDEAYA Biosciences Inc
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
IDEAYA Biosciences Inc
NASDAQ:IDYA
|
Pre-Tax Income
-$178.1m
|
CAGR 3-Years
-69%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Pre-Tax Income
$7.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
19%
|
CAGR 10-Years
4%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Pre-Tax Income
$176m
|
CAGR 3-Years
-73%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
-34%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$4.7B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Pre-Tax Income
$259.6m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Pre-Tax Income
$5B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
IDEAYA Biosciences Inc
Glance View
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 81 full-time employees. The company went IPO on 2019-05-23. The firm is focused on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead synthetic lethality product candidate, IDE397, is a clinical-stage methionine adenosyltransferase 2a (MAT2A) inhibitor for patients with solid tumors having methylthioadenosine phosphorylase (MTAP) deletions. Its clinical-stage product candidate, darovasertib (IDE196), is a protein kinase C (PKC), inhibitor that is being evaluated as a synthetic lethal combination therapy in patients having genetically defined cancers having GNAQ or GNA11 gene mutations. Its pipeline also includes preclinical research programs directed to synthetic lethality targets PARG, Pol Theta, Werner Helicase, and certain deoxyribonucleic acid (DNA) damage targets. The PARG program is for patients having tumors with a defined biomarker based on genetic mutations.
See Also
What is IDEAYA Biosciences Inc's Pre-Tax Income?
Pre-Tax Income
-178.1m
USD
Based on the financial report for Sep 30, 2024, IDEAYA Biosciences Inc's Pre-Tax Income amounts to -178.1m USD.
What is IDEAYA Biosciences Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-35%
Over the last year, the Pre-Tax Income growth was -73%. The average annual Pre-Tax Income growth rates for IDEAYA Biosciences Inc have been -69% over the past three years , -35% over the past five years .
You don't have any saved screeners yet
